TABLE 1.
Characteristics of acute myeloid leukemia patients in the training set and the validation set.
| Characteristic | GSE6891 | TCGA-LAML | p-value |
|---|---|---|---|
| (Training set; n = 429) | (Validation set; n = 151) | ||
| Age at diagnosis, years | <0.0001 | ||
| Median (range) | 44 (18–60) | 56 (21–88) | |
| ≤55 | 361 (84.1) | 74 (49.0) | |
| >55 | 68 (15.9) | 77 (51.0) | |
| Sex | 0.3233 | ||
| Female | 218 (50.8) | 69 (45.7) | |
| Male | 211 (49.2) | 82 (54.3) | |
| FAB classification | 0.0010 | ||
| M0 | 16 (3.7) | 15 (9.9) | |
| M1 | 94 (21.9) | 36 (23.8) | |
| M2 | 100 (23.3) | 37 (24.5) | |
| M3 | 24 (5.6) | 15 (9.9) | |
| M4 | 81 (18.9) | 29 (19.2) | |
| M5 | 100 (23.3) | 15 (9.9) | |
| M6 | 6 (1.4) | 2 (1.3) | |
| M7 | 0 (0) | 1 (0.7) | |
| NA | 8 (1.9) | 1 (0.7) | |
| Cytogenetic risk | 0.0313 | ||
| Good | 91 (21.2) | 31 (20.5) | |
| Intermediate | 245 (57.1) | 81 (53.6) | |
| Poor | 83 (19.3) | 36 (23.8) | |
| NA | 10 (2.3) | 3 (2.0) | |
| Karyotype | 0.0964 | ||
| Others | 351 (81.8) | 127 (84.1) | |
| PML-RARA | 21 (4.9) | 14 (9.3) | |
| RUNX1-RUNX1T1 | 32 (7.5) | 7 (4.6) | |
| NA | 25 (5.8) | 3 (2.0) |
Patients with missing values were removed before performing the statistical tests. Chi-square tests were implemented to compare the constituent ratios of characteristics between the training set GSE6891 and the validation set TCGA-LAML, except for FAB classification, for which Fisher’s exact test was conducted.
FAB, French–American–British; NA, not available; CTC, cell type composition.